Can ondansetron (Zofran) and hydroxyzine cause seizures when given together?

Can Ondansetron (Zofran) and Hydroxyzine Cause Seizures When Given Together?

The combination of ondansetron and hydroxyzine does not directly cause seizures through a synergistic mechanism, but each drug independently carries rare seizure risk, and their co-administration significantly increases the risk of dangerous cardiac arrhythmias through additive QT prolongation. 1, 2, 3

Individual Seizure Risk Profile

Ondansetron (Zofran)

• Rare seizure reports exist in the literature, including case reports of generalized tonic-clonic seizures occurring 12-22 minutes after intravenous ondansetron administration in patients without prior seizure history. 4
• Pediatric overdose cases have documented seizures, including a 12-month-old infant who developed obtundation, myoclonic movements, and seizures after ingesting multiple 8 mg tablets. 5
• The FDA label lists "grand mal seizures" as a rare adverse event, though the relationship to ondansetron was noted as unclear in many cases. 3
• Seizures appear to be dose-related and more common in overdose situations rather than therapeutic dosing. 5, 6

Hydroxyzine

• Documented seizure risk exists, particularly in overdose, with a case report of a 13-month-old child experiencing generalized seizures after accidental ingestion (plasma level 102.7 mcg/ml). 7
• The FDA label does not list seizures as a primary adverse effect but warns about CNS depression and potentiation of other CNS depressants. 2
• Seizure risk appears primarily associated with toxic doses rather than therapeutic administration. 7

The Primary Concern: Additive QT Prolongation

The most clinically significant risk of combining these medications is life-threatening cardiac arrhythmias, not seizures. 1, 2

QT Prolongation Evidence

• Both ondansetron and hydroxyzine are explicitly listed as QT-prolonging medications in pediatric guidelines published by the American Academy of Child and Adolescent Psychiatry. 1
• Hydroxyzine's FDA label specifically warns that cases of QT prolongation and Torsades de Pointes have been reported during post-marketing surveillance, particularly in patients with other risk factors. 2
• Ondansetron can cause QTc prolongation, with the FDA label noting rare reports of transient ECG changes including QT interval prolongation, predominantly with intravenous administration. 3
• The combination creates additive risk for QT prolongation when these medications are used together, as noted in oncology guidelines that specifically caution against combining ondansetron with other QT-prolonging agents. 1

Clinical Monitoring Algorithm

Before Administration

• Obtain baseline ECG if both medications will be used concurrently, particularly if the patient has any cardiac risk factors. 1
• Correct electrolyte abnormalities, especially hypokalemia and hypomagnesemia, before starting treatment. 1
• Screen for additional QT-prolonging medications and consider alternatives if multiple agents are present. 1

Risk Stratification

Avoid this combination in patients with:

• Congenital long QT syndrome or family history of long QT syndrome 2
• Recent myocardial infarction, uncompensated heart failure, or bradyarrhythmias 2
• QTc >500 ms or >60 ms above baseline 1
• History of Torsades de Pointes 2

During Treatment

• Monitor for cardiac symptoms including dizziness, syncope, palpitations, or tachycardia. 1, 2
• Repeat ECG at 7 days after initiation if both drugs are continued, and following any dosing changes. 1
• Use Fridericia, Hodges, or Framingham correction formulas for QTc calculation rather than Bazett formula, which overestimates prolongation. 1
• Discontinue both medications if QTc exceeds 500 ms or if patient develops syncope, tachycardia, or arrhythmia. 1

Additional Monitoring for Seizure Risk

• Observe closely for 30-60 minutes after administration, particularly with intravenous ondansetron, as seizures in case reports occurred within 12-22 minutes. 4
• Use caution in patients with pre-existing seizure disorders, as both medications may lower seizure threshold, though this is not well-established. 1, 4
• Avoid in patients with history of seizures who are not on anticonvulsant therapy, as rimantadine guidelines suggest similar caution for medications affecting seizure threshold. 1

Common Clinical Pitfalls

Do not assume safety based on widespread use. Despite ondansetron's reputation as a safe antiemetic, severe toxicity including seizures can occur, particularly in pediatric populations and overdose situations. 5, 6, 8

Do not overlook the elderly population. Hydroxyzine's FDA label specifically warns that elderly patients are more susceptible to sedation, confusion, and adverse effects, and should start on low doses with close observation. 2

Do not forget about drug-drug interactions beyond QT prolongation. Hydroxyzine's anticholinergic properties can potentiate CNS depression when combined with other CNS depressants, and concomitant use with antihistamines or anticholinergic drugs may increase CNS adverse reactions. 1, 2

Do not use this combination routinely for antiemetic purposes when safer alternatives exist, particularly in outpatient settings where cardiac monitoring is not feasible. 1

Safer Alternative Strategies

• For antiemetic therapy, consider using ondansetron alone at appropriate doses rather than adding hydroxyzine, or substitute with other antiemetics that do not prolong QT interval. 1
• For anxiety with nausea, consider lorazepam as an alternative to hydroxyzine, though benzodiazepines carry their own risks and should be used judiciously. 1
• In high-risk cardiac patients, avoid ondansetron entirely and use alternative antiemetics such as metoclopramide or prochlorperazine with appropriate monitoring for dystonic reactions. 1